Incyte Corp Ltd (INCY): Today's Featured Drugs Laggard

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Incyte ( INCY) pushed the Drugs industry lower today making it today's featured Drugs laggard. The industry as a whole closed the day up 1.3%. By the end of trading, Incyte fell $2.69 (-3.9%) to $66.14 on heavy volume. Throughout the day, 4,155,133 shares of Incyte exchanged hands as compared to its average daily volume of 1,558,800 shares. The stock ranged in price between $65.34-$68.17 after having opened the day at $66.50 as compared to the previous trading day's close of $68.83. Other companies within the Drugs industry that declined today were: Durect Corporation ( DRRX), down 20.5%, Medicines ( MDCO), down 11.5%, Nanoviricides ( NNVC), down 10.6% and Chelsea Therapeutics International ( CHTP), down 7.5%.

Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary small molecule drugs for oncology and inflammation. Incyte has a market cap of $10.6 billion and is part of the health care sector. Shares are up 36.0% year to date as of the close of trading on Wednesday. Currently there are 12 analysts that rate Incyte a buy, 1 analyst rates it a sell, and 1 rates it a hold.

TheStreet Ratings rates Incyte as a sell. The company's weaknesses can be seen in multiple areas, such as its unimpressive growth in net income and generally high debt management risk.

On the positive front, Retrophin ( RTRX), up 49.8%, Conatus Pharmaceuticals ( CNAT), up 19.2%, Cardiome Pharma Corporation ( CRME), up 16.5% and Pacira Pharmaceuticals ( PCRX), up 13.3% , were all gainers within the drugs industry with Amgen ( AMGN) being today's featured drugs industry leader.

For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the drugs industry could consider SPDR S&P Pharmaceuticals ETF ( XPH) while those bearish on the drugs industry could consider ProShares UltraShort Nasdaq Biotech ( BIS).

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

If you liked this article you might like

Clovis Spikes on Phase 3 Data for Ovarian Cancer Drug- Biotech Movers

Cramer: There Should Be More Takeovers Where These Came From

Otonomy Shares Fall On Disappointing Phase 3 Data - Biotech Movers

Eli Lilly Shares Lower After Update on Rheumatoid Arthritis Drug

How Competition Drives Stocks Nowhere: Cramer's 'Mad Money' Recap (Tuesday 7/11/17)